查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1663312

神經栓塞設備 - 市場洞察、競爭格局、2032年市場預測

Neurovascular Embolization Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

2024年全球神經血管栓塞裝置市場規模價值為 13.4766億美元，預計到2032年將達到 18.9084億美元，預測期內（2025-2032年）的年複合成長率為 4.40%。動脈瘤、嚴重頭部創傷、久坐的生活方式和缺血性中風等神經血管疾病的盛行率不斷上升，大大推動了全球神經血管栓塞設備市場的發展。這些疾病通常需要精確、微創治療，而栓塞裝置非常重要。此外，高血壓是神經血管疾病的主要危險因素，全球高血壓發生率上升，導致腦出血和動脈瘤發病率高，進一步增加了對有效栓塞解決方案的需求。

主要市場參與者持續的產品開發活動促成了先進、高效的栓塞設備的推出，改善了患者的治療效果和手術成功率。設備設計、生物相容性和輸送機制的創新提高治療的精確度和安全性，並擴大其在醫療保健提供者中的應用。

大致上，這些因素預計將在2025-2032年的預測期內推動全球神經血管栓塞設備市場顯著成長。

神經血管栓塞裝置的市場動態：

根據Global Burden of Disease（2024），2021年神經系統疾病影響了全球約 43%的人口，約 34億人。緊張型頭痛最常見，影響約20億人，其次是偏頭痛，影響約 11億人。此外，自 1990年以來，全球糖尿病神經病變盛行率增加了兩倍多，到2021年達到 2.06億人。慢性緊張型頭痛常影響血管，而糖尿病神經病變可造成血管損傷，增加動脈瘤和動靜脈畸形（AVM）等神經血管疾病的風險。隨著這些神經系統疾病的發生率上升，對微創治療的需求也日益成長，以降低中風和其他血管併發症的風險。用於阻斷異常血流和封堵動脈瘤的神經血管栓塞裝置在治療這些疾病方面發揮越來越重要的作用，推動了全球市場的成長。

根據這些趨勢，英國心臟基金會（2024）報告指出，全世界約有 5,600萬名女性和 4,500萬名男性是中風倖存者。中風通常是由腦血栓、動脈瘤或腦血管異常形成引起的，需要迅速介入以恢復血流並防止出血。神經血管栓塞裝置，包括線圈、支架和液體栓塞劑，對於治療這些疾病非常重要，它可以阻塞動脈瘤，防止血管破裂，並阻止異常血流流向受損的腦組織，進一步推動市場擴張。

疾病盛行率的上升以及產品開發活動的增加預計將推動市場成長。例如，2021年4月，Medtronic公司獲得FDA批准，生產帶有Shield Technology（TM）的Pipeline（TM）Flex神經血管栓塞裝置，該裝置目的是減少血栓形成並降低血流改道手術期間血栓形成的風險。

在這些成長動力中，某些挑戰也可能阻礙市場的發展。與栓塞相關的併發症，例如微導管、微導絲和線圈造成的動脈瘤穿孔，會帶來手術風險。此外，嚴格的監管審批流程可能會延遲產品推出並抑制市場成長。

北美預計將主導整個神經栓塞設備市場

預計到2024年北美將佔據全球神經血管栓塞設備市場的最大佔有率。該地區市場的成長主要得益於動脈瘤、高血壓和出血等神經血管疾病的高發性、產品開發活動的增加以及政府的支持措施。預計這些因素將在預測期內（2025-2032年）對市場擴張做出重大貢獻。

本報告研究了全球神經栓塞設備市場，提供了市場規模和預測、過去三年的產品/技術發展、市場主要參與者和可用機會的資訊。

目錄

第1章 神經血管栓塞設備市場報告簡介

第2章 神經栓塞設備市場執行摘要

  • 市場概況

第3章 競爭格局

第4章 監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第5章 神經血管栓塞設備市場的關鍵因素分析

  • 神經血管栓塞設備市場驅動因素
  • 神經栓塞裝置市場的限制與挑戰
  • 神經血管栓塞裝置的市場機會

第6章 神經血管栓塞設備市場的波特五力分析

第7章 神經栓塞設備市場評估

  • 依產品類型
    • 栓塞線圈
    • 神經血管線圈輔助裝置
    • 液體栓塞系統
    • 導流支架
    • 囊內血流擾亂器
    • 其他
  • 依最終用戶
    • 醫院
    • 門診手術中心
  • 區域
    • 北美洲
    • 歐洲
    • 亞太地區
    • 其他地區

第8章 神經血管栓塞設備市場中的公司與產品概況

  • Medtronic PLC
  • Stryker
  • MicroVention, Inc. (Terumo Corporation)
  • Johnson & Johnson Services, Inc.
  • Penumbra, Inc.
  • B. Braun Melsungen AG
  • Acandis GmbH
  • Wallaby Medical.
  • Shape Memory Medical Inc.
  • Zylox-Tonbridge Medical Technology Co., Ltd.
  • Spartan Micro, Inc.
  • KANEKA CORPORATION
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Meril Life Sciences Pvt. Ltd.
  • Boston Scientific Corporation
  • phenox GmbH
  • Merit Medical Systems.
  • Perflow Medical Ltd.
  • MicroPort Scientific Corporation.
  • Cerus Endovascular

第9章 KOL 視角

第10章 專案方法

第11章 關於 DelveInsight

第12章 免責聲明、聯絡我們

Product Code: DIMDCL0477

Neurovascular Embolization Device Market by Product Type (Embolization Coils, Neurovascular Coil Assist Devices [Coil Assist Stents and Coil Assist Balloons], Liquid Embolization Systems, Flow Diversion Stents, Intrasaccular Flow Disruptor, and Others), By End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of neurovascular disorders, increase in prevalence of hypertension across the globe, and increase in product development activities by the key market players across the globe.

The neurovascular embolization devices market was valued at USD 1,347.66 million in 2024, growing at a CAGR of 4.40% during the forecast period from 2025 to 2032, to reach USD 1,890.84 million by 2032. The rising prevalence of neurovascular disorders such as aneurysms, severe head injuries, sedentary lifestyles, and ischemic strokes is significantly driving the global market for neurovascular embolization devices. These conditions often require precise, minimally invasive treatments, for which embolization devices are critical. Additionally, the global increase in hypertension a major risk factor for neurovascular diseases has led to a higher incidence of brain hemorrhages and aneurysms, further fueling demand for effective embolization solutions.

Ongoing product development efforts by key market players are introducing advanced and efficient embolization devices, improving patient outcomes and procedural success rates. Innovations in device design, biocompatibility, and delivery mechanisms are enhancing treatment precision and safety, thereby expanding adoption among healthcare providers.

Collectively, these factors are expected to drive substantial growth in the global neurovascular embolization devices market during the forecast period from 2025 to 2032.

Neurovascular Embolization Devices Market Dynamics:

According to the Global Burden of Disease (2024), neurological conditions affected approximately 43% of the global population in 2021, impacting around 3.4 billion individuals. Among these, tension-type headaches were the most prevalent, with an estimated 2 billion cases, followed by migraines affecting approximately 1.1 billion people. Additionally, the global prevalence of diabetic neuropathy has more than tripled since 1990, reaching 206 million cases in 2021. Chronic tension headaches often have vascular implications, while diabetic neuropathy can lead to vascular damage, increasing the risk of neurovascular conditions such as aneurysms and arteriovenous malformations (AVMs). As the incidence of these neurological disorders rises, the demand for minimally invasive treatments to mitigate the risks of stroke and other vascular complications is growing. Neurovascular embolization devices used to block abnormal blood flow or seal aneurysms play an increasingly vital role in addressing these conditions, thereby driving global market growth.

Complementing these trends, the British Heart Foundation (2024) reported that approximately 56 million women and 45 million men worldwide were stroke survivors. Strokes, often caused by blood clots, aneurysms, or abnormal blood vessel formations in the brain, require prompt intervention to restore blood flow and prevent hemorrhagic events. Neurovascular embolization devices including coils, stents, and liquid embolic agents are essential in treating these conditions by sealing aneurysms, preventing vessel ruptures, and blocking abnormal blood flow to damaged brain tissue, further propelling market expansion.

In addition to rising disease prevalence, increasing product development activities are expected to bolster market growth. For instance, in April 2021, Medtronic plc received FDA approval for its Pipeline(TM) Flex Neurovascular Embolization Device with Shield Technology(TM), designed to reduce thrombogenicity and lower the risk of clot formation during flow diversion therapy.

Despite these growth drivers, certain challenges may impede market progress. Complications associated with embolization procedures such as aneurysmal perforations caused by micro catheters, micro-guidewires, or coils pose procedural risks. Moreover, stringent regulatory approval processes can delay product launches, potentially restraining market growth.

Neurovascular Embolization Devices Market Segment Analysis:

Neurovascular Embolization Device Market by Product Type (Embolization Coils, Neurovascular Coil Assist Devices [Coil Assist Stents and Coil Assist Balloons], Liquid Embolization Systems, Flow Diversion Stents, Intrasaccular Flow Disruptor, and Others), By End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the global neurovascular embolization devices market, embolization coils are projected to hold the largest share in 2024. These coils, typically made from platinum or other biocompatible materials, are inserted into aneurysms to promote clot formation, effectively sealing the aneurysm and preventing rupture. As a minimally invasive alternative to open surgery, embolization coils offer patients faster recovery times and lower complication risks, making them a preferred choice in neurovascular procedures.

Technological advancements such as improved coil flexibility, enhanced precision, and better radiopacity have further driven their adoption in both emergency and elective neurovascular treatments. These innovations enable physicians to navigate complex vascular anatomies more efficiently, improving procedural success rates and patient outcomes.

Moreover, increased funding for the development and commercialization of neurovascular embolization coils is contributing to market growth. For example, in July 2021, Zylox-Tonbridge Medical Technology Co., Ltd. raised USD 329 million to support the development of its core neurovascular products, including embolization coils and micro catheters for coiling procedures.

Collectively, these factors are expected to generate significant revenue for the embolization coil segment, driving the overall growth of the global neurovascular embolization devices market during the forecast period.

North America is expected to dominate the overall neurovascular embolization devices market:

North America is projected to hold the largest share of the global neurovascular embolization devices market in 2024. The region's market growth is primarily driven by the high prevalence of neurovascular disorders such as aneurysms, hypertension, and hemorrhages coupled with increasing product development activities and supportive government initiatives. These factors are expected to significantly contribute to market expansion during the forecast period (2025 to 2032).

According to the Brain Aneurysm Foundation (2024), an estimated 6.8 million people in the United States approximately 1 in 50 individuals were living with an unruptured brain aneurysm in 2021. The annual rupture rate ranged from 8 to 10 per 100,000 people, with approximately 30,000 aneurysm ruptures occurring each year, translating to one rupture every 18 minutes. This growing diagnosis rate of both ruptured and unruptured aneurysms underscores the need for advanced, minimally invasive treatment solutions. Neurovascular embolization devices including coils, flow diverters, and stents are pivotal in preventing aneurysm ruptures and managing bleeding, offering safer alternatives to traditional open surgeries.

Similarly, the prevalence of strokes further escalates market demand. As per the Centers for Disease Control and Prevention (CDC, 2024), a stroke occurs every 40 seconds in the United States, affecting over 795,000 individuals annually. Of these, approximately 610,000 are first-time strokes, while around 185,000 occur in individuals with a prior stroke. Ischemic strokes caused by blocked blood flow to the brain account for about 87% of these cases. With hypertension being a leading risk factor for both ischemic and hemorrhagic strokes, the growing hypertensive population elevates the incidence of aneurysms, arteriovenous malformations (AVMs), and other neurovascular conditions. Consequently, this drives the need for neurovascular embolization devices to effectively manage and treat these conditions.

Government initiatives aimed at improving brain aneurysm research are further propelling market growth. For example, in March 2021, during the 117th Congressional Session, the U.S. government allocated USD 10 million annually from 2022 to 2030 to support comprehensive research on unruptured intracranial aneurysms, with funds available through September 30, 2029. Such funding is instrumental in fostering technological advancements and improving patient care.

In conclusion, the combination of a high disease burden, technological advancements, supportive policy measures, and increased public awareness is expected to bolster the North American neurovascular embolization devices market during the forecast period.

Neurovascular Embolization Devices Market Key Players:

Some of the key market players operating in the neurovascular embolization devices market include Medtronic PLC, Stryker, MicroVention, Inc. (Terumo Corporation), Johnson & Johnson Services, Inc., Penumbra, Inc., B. Braun Melsungen AG, Acandis GmbH, Wallaby Medical., Shape Memory Medical Inc., Zylox-Tonbridge Medical Technology Co., Ltd., Spartan Micro, Inc., KANEKA CORPORATION, Lepu Medical Technology(Beijing)Co., Ltd., Meril Life Sciences Pvt. Ltd., Boston Scientific Corporation, phenox GmbH, Merit Medical Systems., Perflow Medical Ltd., MicroPort Scientific Corporation., Cerus Endovascular, and others.

Recent Developmental Activities in the Neurovascular Embolization Devices Market:

  • In July 2024, MicroVention, Inc., a neurovascular company and subsidiary of Terumo Corporation, announced the publication of the CLEVER trial results. This multicenter, prospective study involved 163 patients across 17 European centers. Investigators assessed the safety and effectiveness of MicroVention's Woven EndoBridge (WEB) 17 system for treating ruptured and unruptured aneurysms. The WEB 17 is the company's newest and smallest aneurysm embolization system.

Key Takeaways from the Neurovascular Embolization Devices Market Report Study:

  • Market size analysis for current neurovascular embolization devices size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the neurovascular embolization devices market.
  • Various opportunities available for the other competitors in the neurovascular embolization devices market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current neurovascular embolization devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for neurovascular embolization devices market growth in the coming future?

Target Audience Who Can be Benefited from this Neurovascular Embolization Devices Market Report Study:

  • Neurovascular embolization device providers
  • Research organizations and consulting companies
  • Neurovascular embolization devices -related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in neurovascular embolization devices
  • Various end-users who want to know more about the neurovascular embolization devices market and the latest technological developments in the neurovascular embolization devices market.

Frequently Asked Questions for the Neurovascular Embolization Devices Market:

1. What are neurovascular embolization devices?

  • A neurovascular embolization device is an intravascular implant intended to permanently occlude blood flow to cerebral aneurysms and cerebral arteriovenous malformations.

2. What is the market for neurovascular embolization devices?

  • The neurovascular embolization devices market was valued at USD 1,3477.66 million in 2024, growing at a CAGR of 4.40% during the forecast period from 2025 to 2032, to reach USD 1,890.84 million by 2032.

3. What are the drivers for the neurovascular embolization devices market?

  • The growing prevalence of neurovascular disorders, such as aneurysms, severe head injuries, sedentary lifestyles, and ischemic strokes, is significantly boosting the market for neurovascular embolization devices. Additionally, the global rise in hypertension, a major risk factor for neurovascular diseases, has increased the number of patients susceptible to conditions like brain hemorrhages and aneurysms, thus driving the demand for effective embolization devices. Furthermore, increased product development activities by key market players across the globe are introducing more advanced and efficient embolization solutions, improving outcomes for patients and enhancing procedural success. Together, these factors are expanding the global market for neurovascular embolization devices.

4. Who are the key players operating in the neurovascular embolization devices market?

  • Some of the key market players operating in the neurovascular embolization devices market include Medtronic PLC, Stryker, MicroVention, Inc. (Terumo Corporation), Johnson & Johnson Services, Inc., Penumbra, Inc., B. Braun Melsungen AG, Acandis GmbH, Wallaby Medical., Shape Memory Medical Inc., Zylox-Tonbridge Medical Technology Co., Ltd., Spartan Micro, Inc., KANEKA CORPORATION, Lepu Medical Technology(Beijing)Co., Ltd., Meril Life Sciences Pvt. Ltd., Boston Scientific Corporation, phenox GmbH, Merit Medical Systems., Perflow Medical Ltd., MicroPort Scientific Corporation., Cerus Endovascular, and others.

5. Which region has the highest share in the neurovascular embolization devices market?

  • Among all the regions, North America is expected to hold the largest share of the global neurovascular embolization devices market in 2024. The growing prevalence of neurovascular disorders, such as aneurysms, hypertension, hemorrhages, and others is expected to boost the market across the region. Additionally, recent product developmental activities and rising government initiatives are expected to aid in the growth of the North American neurovascular embolization devices market during the forecast period from 2025 to 2032.

Table of Contents

1. Neurovascular Embolization Devices Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Neurovascular Embolization Devices Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Neurovascular Embolization Devices Market Key Factors Analysis

  • 5.1. Neurovascular Embolization Devices Market Drivers
    • 5.1.1. Growing prevalence of neurovascular disorders such as brain aneurysm, hemorrhage, and others due to severe head injuries, sedentary lifestyle, others
    • 5.1.2. Increase in prevalence of hypertension across the globe
    • 5.1.3. Increase in product development activities by key market players across the globe
  • 5.2. Neurovascular Embolization Devices Market Restraints and Challenges
    • 5.2.1. Complications associated with embolization coils
    • 5.2.2. Stringent regulatory approvals
  • 5.3. Neurovascular Embolization Devices Market Opportunities
    • 5.3.1. Continuous innovations in embolization technology, including more precise, flexible, and safer devices

6. Neurovascular Embolization Devices Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Neurovascular Embolization Devices Market Assessment

  • 7.1. By Product Type
    • 7.1.1. Embolization Coils
    • 7.1.2. Neurovascular Coil Assist Devices
      • 7.1.2.1. Coil Assist Stents
      • 7.1.2.2. Coil Assist Balloons
    • 7.1.3. Liquid Embolization Systems
    • 7.1.4. Flow Diversion Stents
    • 7.1.5. Intrasaccular Flow Disruptor
    • 7.1.6. Others
  • 7.2. By End-User
    • 7.2.1. Hospitals
    • 7.2.2. Ambulatory Surgical Centers
    • 7.2.3. Others
  • 7.3. By Geography
    • 7.3.1. North America
      • 7.3.1.1. United States Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.1.2. Canada Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.1.3. Mexico Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
    • 7.3.2. Europe
      • 7.3.2.1. France Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.2.2. Germany Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.2.3. United Kingdom Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.2.4. Italy Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.2.5. Spain Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.2.6. Rest of Europe Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
    • 7.3.3. Asia-Pacific
      • 7.3.3.1. China Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.3.2. Japan Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.3.3. India Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.3.4. Australia Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.3.5. South Korea Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.3.6. Rest of Asia-Pacific Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
    • 7.3.4. Rest of the World (RoW)
      • 7.3.4.1. Middle East Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.4.2. Africa Neurovascular Embolization Devices Market Size in USD Million (2022-2032)
      • 7.3.4.3. South America Neurovascular Embolization Devices Market Size in USD Million (2022-2032)

8. Neurovascular Embolization Devices Market Company and Product Profiles

  • 8.1. Medtronic PLC
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Stryker
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. MicroVention, Inc. (Terumo Corporation)
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Johnson & Johnson Services, Inc.
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Penumbra, Inc.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. B. Braun Melsungen AG
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Acandis GmbH
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Wallaby Medical.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Shape Memory Medical Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Zylox-Tonbridge Medical Technology Co., Ltd.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Spartan Micro, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. KANEKA CORPORATION
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Lepu Medical Technology (Beijing)Co., Ltd.
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Meril Life Sciences Pvt. Ltd.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Boston Scientific Corporation
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. phenox GmbH
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Merit Medical Systems.
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Perflow Medical Ltd.
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. MicroPort Scientific Corporation.
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Cerus Endovascular
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Neurovascular Embolization Devices Market in Global (2022-2032)
  • Table 3: Neurovascular Embolization Devices Market in Global by Product Type (2022-2032)
  • Table 4: Neurovascular Embolization Devices Market in Global by End-User (2022-2032)
  • Table 5: Neurovascular Embolization Devices Market in Global by Geography (2022-2032)
  • Table 6: Neurovascular Embolization Devices Market in North America (2022-2032)
  • Table 7: Neurovascular Embolization Devices Market in the United States (2022-2032)
  • Table 8: Neurovascular Embolization Devices Market in Canada (2022-2032)
  • Table 9: Neurovascular Embolization Devices Market in Mexico (2022-2032)
  • Table 10: Neurovascular Embolization Devices Market in Europe (2022-2032)
  • Table 11: Neurovascular Embolization Devices Market in France (2022-2032)
  • Table 12: Neurovascular Embolization Devices Market in Germany (2022-2032)
  • Table 13: Neurovascular Embolization Devices Market in United Kingdom (2022-2032)
  • Table 14: Neurovascular Embolization Devices Market in Italy (2022-2032)
  • Table 15: Neurovascular Embolization Devices Market in Spain (2022-2032)
  • Table 16: Neurovascular Embolization Devices Market in the Rest of Europe (2022-2032)
  • Table 17: Neurovascular Embolization Devices Market in Asia-Pacific (2022-2032)
  • Table 18: Neurovascular Embolization Devices Market in China (2022-2032)
  • Table 19: Neurovascular Embolization Devices Market in Japan (2022-2032)
  • Table 20: Neurovascular Embolization Devices Market in India (2022-2032)
  • Table 21: Neurovascular Embolization Devices Market in Australia (2022-2032)
  • Table 22: Neurovascular Embolization Devices Market in South Korea (2022-2032)
  • Table 23: Neurovascular Embolization Devices Market in Rest of Asia-Pacific (2022-2032)
  • Table 24: Neurovascular Embolization Devices Market in the Rest of the World (2022-2032)
  • Table 25: Neurovascular Embolization Devices Market in the Middle East (2022-2032)
  • Table 26: Neurovascular Embolization Devices Market in Africa (2022-2032)
  • Table 27: Neurovascular Embolization Devices Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Neurovascular Embolization Devices Market in Global (2022-2032)
  • Figure 3: Neurovascular Embolization Devices Market in Global by Product Type (2022-2032)
  • Figure 4: Neurovascular Embolization Devices Market in Global by End-User (2022-2032)
  • Figure 5: Neurovascular Embolization Devices Market in Global by Geography (2022-2032)
  • Figure 6: Neurovascular Embolization Devices Market in North America (2022-2032)
  • Figure 7: Neurovascular Embolization Devices Market in the United States (2022-2032)
  • Figure 8: Neurovascular Embolization Devices Market in Canada (2022-2032)
  • Figure 9: Neurovascular Embolization Devices Market in Mexico (2022-2032)
  • Figure 10: Neurovascular Embolization Devices Market in Europe (2022-2032)
  • Figure 11: Neurovascular Embolization Devices Market in France (2022-2032)
  • Figure 12: Neurovascular Embolization Devices Market in Germany (2022-2032)
  • Figure 13: Neurovascular Embolization Devices Market in United Kingdom (2022-2032)
  • Figure 14: Neurovascular Embolization Devices Market in Italy (2022-2032)
  • Figure 15: Neurovascular Embolization Devices Market in Spain (2022-2032)
  • Figure 16: Neurovascular Embolization Devices Market in the Rest of Europe (2022-2032)
  • Figure 17: Neurovascular Embolization Devices Market in Asia-Pacific (2022-2032)
  • Figure 18: Neurovascular Embolization Devices Market in China (2022-2032)
  • Figure 19: Neurovascular Embolization Devices Market in Japan (2022-2032)
  • Figure 20: Neurovascular Embolization Devices Market in India (2022-2032)
  • Figure 21: Neurovascular Embolization Devices Market in Australia (2022-2032)
  • Figure 22: Neurovascular Embolization Devices Market in South Korea (2022-2032)
  • Figure 23: Neurovascular Embolization Devices Market in Rest of Asia-Pacific (2022-2032)
  • Figure 24: Neurovascular Embolization Devices Market in the Rest of the World (2022-2032)
  • Figure 25: Neurovascular Embolization Devices Market in the Middle East (2022-2032)
  • Figure 26: Neurovascular Embolization Devices Market in Africa (2022-2032)
  • Figure 27: Neurovascular Embolization Devices Market in South America (2022-2032)
  • Figure 28: Market Drivers
  • Figure 29: Market Barriers
  • Figure 30: Market Opportunities
  • Figure 31: PORTER'S Five Force Analysis